On the heels of the recent funding round from a group of investors which raised $600,000, Byteflies is teaming-up with the biopharmaceutical company UCB to monitor difficult to measure seizures experienced by people with epilepsy.
The company has the ambition to become the reference in wearable health solutions, offering what it says is a "unique toolkit of specialized wearables" along with an accompanying data platform that targets the pharmaceutical industry, start-ups and research groups.
Currently, Byteflies' wearables are being used in a monitoring project for UCB. As part of a consortium — which includes UCB, the University of Leuven, the Leuven University Hospital and product developer PiliPili — the company is providing discreet and accurate monitoring of difficult to measure seizures in a test group of patients.
"In partnership with Byteflies, UCB is excited to be at the forefront of next generation wearables, collaborating to evaluate the benefits of measuring patient symptoms and experiences which, in the future, could support individually tailored care approaches" says Erik Janssen, VP, Head of Innovative Solutions, Neurology Patient Value Unit, UCB. "Everything we do at UCB is Inspired by patients, and Driven by science. In this regard, harnessing technology and innovation are crucial elements in our mission to provide maximum value to those patients who need it the most".
Headquartered in Belgium, Byteflies also has an office in Silicon Valley. Before the end of this year, the company plans to launch its very own wearable health toolkit which promises to dramatically accelerate clinical trials and research.